XFOR X4 Pharmaceuticals, Inc: מקדם חוב לטווח ארוך להון

X4 Pharmaceuticals generates revenue through the implementation of innovative mavorixafor therapy to combat WHIM syndrome. The long-term debt-to-equity ratio on the GURU.Markets chart helps assess the risks of a narrow sales market and physician conservatism, with the latest parameter standing at 0.47. Current prescription dynamics ensure a steady cash flow, turning the asset into a reliable cash cow.

The long-term debt-to-equity ratio determines the proportion of liabilities with a maturity exceeding one year within the financing structure. By analyzing the historical trend of long-term debt to equity, an investor assesses the degree of financial leverage. This metric is sensitive to the market value of shares and the volume of loans secured. For X4 Pharmaceuticals (XFOR), the balance of borrowings is critical when establishing costly pharmaceutical logistics infrastructure. Optimizing this indicator reduces bankruptcy risks during the deployment of supply chains.